The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiploma Regulatory News (DPLM)

Share Price Information for Diploma (DPLM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3,828.00
Bid: 3,828.00
Ask: 3,830.00
Change: 12.00 (0.31%)
Spread: 2.00 (0.052%)
Open: 3,814.00
High: 3,854.00
Low: 3,798.00
Prev. Close: 3,816.00
DPLM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

14 Jan 2009 07:00

RNS Number : 5894L
Diploma PLC
14 January 2009
 



<>

12 CHARTERHOUSE SQUARE, LONDON EC1M 6AX

TELEPHONE: +44 (0)20 7549 5700

FACSIMILE: +44 (0)20 7549 5715

FOR IMMEDIATE RELEASE

14 January 2009

DIPLOMA PLC

INTERIM MANAGEMENT STATEMENT

Diploma PLC, the international group of businesses supplying specialised technical products and services, is today issuing its first Interim Management Statement of the new financial yearahead of the Company's AGM to be held today at Brewers Hall, Aldermanbury SquareLondon, EC2V 7HR at 12.00 midday. This Statement relates to the period from 1 October 2008 to 31 December 2008 and includes the first quarter's trading.

The Group continues to benefit from its focus on specialised sectors and supplying essential products and services which are mostly funded by customers' operating, rather than capital, budgets.  With more than 60% of revenues generated outside the UK, the Group has also gained on translation from the significant deterioration in the value of UK sterling relative to all other major currencies. With this background, the Board is able to report an increase in Group revenues of 2% over the comparable period last year although, on a constant currency basis, Group revenues reduced by 7% over the comparable period.

In Life Sciences, the Canadian Healthcare businesses, which account for over 50% of sector revenue, continued to show steady development.  Revenue from the European businesses were somewhat reduced against a strong comparable quarter last year.

Trading in the US Seals businesses weakened in the quarter, reflecting the difficult market conditions in the broader US industrial economy. Cost reduction programmes implemented in the US operations have partly mitigated the effects of reduced operational leverage. By contrast, the performance of the European Seals businesses was strong.

In Controls, the European businesses overall delivered a steady performance, with a continued focus on relatively more buoyant, technically driven sectors. 

The deterioration in the value of UK sterling relative to all other major currencies has had a significant positive impact on the Group's results on translation. Against the comparable period last year, the US dollarthe Euro and the Canadian dollar have appreciated by 25%, 16% and 6% respectively against UK sterling. Conversely at a transaction level, the weakness of UK sterling and the deterioration of the Canadian dollar relative to the US dollar, has put pressure on gross margins in the UK and Canadian businesses, by increasing the cost of goods sold.

The Group continued to maintain a strong financial position with cash balances of £16.6m at 31 December 2008 and undrawn committed term facilities of £25.0m.

On 23 December 2008, the Group announced that it had signed contracts to acquire RT/Dygerta leading supplier of seals, o-rings and custom moulded and machine parts, based in the US, for a maximum consideration of £13.2m (US$19.75m). This acquisition formally closed on 12 January 2009 and the initial consideration paid of £9.6m (US$14.4m) has been funded in part from the Group's existing cash resources and in part by drawing down £4.7m (US$7.0m) from the Group's committed bank facility. This acquisition is expected to be immediately earnings enhancing for the Group.

In addition, as reported in the 2008 Annual Report, on 5 November 2008, the Group acquired Meditech, a small medical diagnostic company in Canada for a maximum consideration of £1.5m (C$2.9m). On completion, the initial consideration of £1.3m (C$2.4m) was funded out of the Group's existing cash resources.

Finally, pursuant to the sale and purchase agreement signed on 28 August 2007, the Group will shortly be making a payment to the vendors of AMT of £1.1m (C$2.0m) as deferred consideration. This payment was based on the performance of that business during the year ended 30 September 2008.

There have been no other significant changes in the position of the Group in the period since the publication of the Annual Report for the year ended 30 September 2008.

The next update on trading is expected to be issued as part of the Half Year results for the six months ending 31 March 2009, which are expected to be released on 11 May 2009.

Notes:

This Interim Management Statement, which is based upon unaudited management accounts, has been prepared solely to provide additional information to the shareholders of Diploma PLC in order to meet the requirements of the UK Listing Authority's Disclosure and Transparency Rules. It should not be relied on by any other party, for other purposes.

A copy of this Statement, together with further information about Diploma PLC, may be viewed on its website at www.diplomaplc.com

For further enquiries please contact:

Bruce Thompson, Chief Executive Officer

020 7549 5700

Nigel Lingwood, Group Finance Director

020 7549 5705

Simon Bloomfield, Bankside Consultants

020 7367 8861

NOTE TO EDITORS:

Diploma PLC is an international group of businesses supplying specialised technical products and services to the Life Sciences, Seals and Controls industries.

Diploma achieves stable growth and attractive margins from its focus on supplying specialised technical products to markets which value high levels of customer service, technical support and value adding activities. A high proportion of revenues are generated from essential products and services funded by operating, rather than capital budgets.

The Group employs ca. 1,000 employees and its principal operating businesses are located in the UKGermany, US and Canada.

Over the last five years, the Group has grown adjusted earnings per share at an average of ca. 21% p.a. through a combination of organic growth and acquisitions. The current market capitalisation is ca. £150m.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSEAXFDFSFNEFE
Date   Source Headline
2nd May 20247:00 amRNSAcquisition
25th Apr 20243:54 pmRNSHolding(s) in Company
3rd Apr 20247:00 amRNSHolding(s) in Company
27th Mar 20247:00 amRNSAcquisition
5th Mar 20242:07 pmRNSHolding(s) in Company
17th Jan 20243:21 pmRNSResult of AGM
17th Jan 20247:00 amRNSQ1 trading update
20th Dec 20237:00 amRNSAppointment of Non-Executive Director
18th Dec 20237:00 amRNSDirector/PDMR Shareholding
14th Dec 202311:31 amRNSHolding(s) in Company
11th Dec 20237:00 amRNSAnnual Financial Report & Notice of AGM
5th Dec 20233:00 pmRNSDirector/PDMR Shareholding
1st Dec 20237:00 amRNSTotal Voting Rights
28th Nov 20237:00 amRNSDirector/PDMR Grant of LTIP Awards
21st Nov 20237:00 amRNSDirector/PDMR Shareholding
20th Nov 20237:00 amRNSFull Year Results
16th Nov 20237:00 amRNSIssue of Shares & Total Voting Rights
10th Oct 202312:29 pmRNSHolding(s) in Company
21st Aug 202310:10 amRNSHolding(s) in Company
15th Aug 20233:54 pmRNSHolding(s) in Company
18th Jul 20237:00 amRNSDirector/PDMR Shareholding
13th Jul 20237:00 amRNSStrategic acquisition in European Fluid Power
13th Jul 20237:00 amRNSQ3 Trading Update
27th Jun 20237:00 amRNSCapital Markets Seminar
13th Jun 20235:09 pmRNSHolding(s) in Company
7th Jun 20233:49 pmRNSHolding(s) in Company
30th May 20237:00 amRNSAppointment of Non-Executive Director
22nd May 20233:30 pmRNSHolding(s) in Company
15th May 20237:00 amRNSHalf-year Report
3rd Apr 20237:00 amRNSTotal Voting Rights
27th Mar 202310:34 amRNSHolding(s) in Company
24th Mar 20234:00 pmRNSDirector/PDMR Shareholding
23rd Mar 20232:34 pmRNSHolding(s) in Company
22nd Mar 20237:00 amRNSIssue of Shares and Total Voting Rights
22nd Mar 20237:00 amRNSDirector/PDMR Shareholding
20th Mar 20239:14 amRNSHolding(s) in Company
17th Mar 20236:00 pmRNSDiploma
17th Mar 20237:00 amRNSResult of Placing
16th Mar 20234:47 pmRNSRetail Offer
16th Mar 20234:46 pmRNSProposed Placing
16th Mar 20234:45 pmRNSAcquisition and M&A Pipeline Update
20th Feb 20239:35 amRNSHolding(s) in Company
9th Feb 20238:27 amRNSHolding(s) in Company
30th Jan 20232:53 pmRNSHolding(s) in Company
19th Jan 20237:00 amRNSDirector/PDMR Grant of LTIP Award
18th Jan 202311:13 amRNSResult of AGM
18th Jan 20237:00 amRNSTrading Statement
12th Dec 20227:00 amRNSAnnual Financial Report & Notice of AGM
9th Dec 202210:33 amRNSHolding(s) in Company - Replacement
8th Dec 20229:41 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.